ImmunID to Collaborate with IRX Therapeutics on Test to Predict Immunotherapy Response | GenomeWeb

NEW YORK (GenomeWeb) – ImmunID announced today that it is working with IRX Therapeutics, a clinical-stage cancer immunotherapy developer, to predict response to IRX's investigational drug IRX-2.

Under the terms of the collaboration, ImmunID will use its ImmunTracker technology to assess the immune-modulatory effect of IRX-2 in a randomized phase 2b study of patients with newly diagnosed head and neck squamous cell cancer. The trial is designed to determine whether neoadjuvant treatment with IRX-2 — before an attempt at curative surgery — can reduce the risk of later recurrence.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.